I-02 Donghwan Lee Quantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD) Wednesday 10:15-11:45 |
I-05 Annabelle Lemenuel Diot Identification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model Wednesday 10:15-11:45 |
I-14 James Lu Refining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model) Wednesday 10:15-11:45 |
I-28 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases. Wednesday 10:15-11:45 |
I-35 Ronald Niebecker Modelling of Anti-Drug Antibodies Directed Against a Monoclonal Antibody Wednesday 10:15-11:45 |
I-51 Sabine Pilari Mathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement Therapy Wednesday 10:15-11:45 |
I-62 Hyerang Roh Quantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosin Wednesday 10:15-11:45 |
I-68 Vargo Ryan Comparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for Cmax Wednesday 10:15-11:45 |
II-01 Teijo Saari Significant changes in pharmacokinetics of sufentanil during target controlled infusion of sufentanil for cardiac anaesthesia. Wednesday 15:10-16:40 |
II-14 Hanna Silber Baumann Population pharmacokinetics of cyclosporine A in cats Wednesday 15:10-16:40 |
II-16 Nicolas Simon A joint PK/PD-PD model of levodopa in patients with Parkinson's disease: Motor effect and Movement disorder Wednesday 15:10-16:40 |
II-17 Jean Smeets Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives Wednesday 15:10-16:40 |
II-23 David Stepensky Inter-patient variability of local vs. systemic effects of TNF-α-neutralizing antibodies in rheumatoid arthritis Wednesday 15:10-16:40 |
II-24 Jasper Stevens Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients Wednesday 15:10-16:40 |
II-25 Elisabet Størset Population pharmacokinetics of tacrolimus to aid individualized dosing in kidney transplant recipients Wednesday 15:10-16:40 |
II-26 Fran Stringer A Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy Wednesday 15:10-16:40 |
II-28 Herbert Struemper Target-mediated clearance of ofatumumab: a tale of different disease states Wednesday 15:10-16:40 |
II-31 Takeshi Tajima Mechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers Wednesday 15:10-16:40 |
II-33 David Ternant A model predicting expected infliximab serum concentrations using only dose and time since last infusion Wednesday 15:10-16:40 |
II-49 Nageshwar Budha Population Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab Wednesday 15:10-16:40 |
II-54 Bing Wang Population pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients Wednesday 15:10-16:40 |
II-61 Stefano Zamuner PK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect. Wednesday 15:10-16:40 |
II-62 Stefan Zeiser Population PK Modeling of Dapivirine Released from Vaginal Rings Wednesday 15:10-16:40 |
III-07 Jacqueline Anderson PKPD modelling of human chlorpyrifos poisoning Thursday 10:05-11:35 |
III-10 Daren Austin A closed-form solution set-point model of treatment response in multiple diseases Thursday 10:05-11:35 |
III-11 Nicolas Azzopardi Modelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT) Thursday 10:05-11:35 |
III-16 Aliénor Bergès Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis Thursday 10:05-11:35 |
III-17 Tarjinder Sahota A mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers Thursday 10:05-11:35 |
III-30 Thierry Buclin Monitoring Blood Prostate-Specific Antigen (PSA) after Radical Prostatectomy Thursday 10:05-11:35 |
III-34 Yu-Jung Cha Population Pharmacokinetics of Etanercept in Healthy Korean Male Volunteers Thursday 10:05-11:35 |
III-60 Anne Dubois Joint modelling of the placebo response and the dropout mechanism using clinical data from a trial performed in patients suffering from major depressive disorder Thursday 10:05-11:35 |
III-69 Martin Fink Population pharmacokinetic analysis of robenacoxib in dogs with chronic osteoarthritis Thursday 10:05-11:35 |
IV-04 Nicolas Frey Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis Thursday 15:00-16:30 |
IV-09 Samira Garonzik Development of PK/PD Models to describe Pharmacokinetics and Biomarker Responses for Dovitinib (TKI258) Thursday 15:00-16:30 |
IV-10 Peter Gennemark Experimental design based on mechanistic mathematical modeling of body composition and energy turnover Thursday 15:00-16:30 |
IV-12 Massimiliano Germani Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole. Thursday 15:00-16:30 |
IV-38 Daniel Hovdal A mechanism-based population model for estimation of system parameters, vehicle effects and drug-induced body weight changes in diet induced obesity mice Thursday 15:00-16:30 |